Thomsen LM. Patient safety in relation to biosimilars – how can we act as a patient organisation? EULAR 2017, OP0328-PARE.
Bimekizumab behaalt als eerste primair eindpunt ASAS40-respons na 12 weken
jun 2018 | Spondyloartritis
nov 2022 | Psoriasis
nov 2020
okt 2020
aug 2020 | RA, SLE